Apogee Therapeutics secured up to $1.3 billion in non-dilutive financing from Blackstone Life Sciences to move zumilokibart into Phase 3 development for atopic dermatitis. The funding deal is tied to development and commercialization milestones. Apogee also pointed to positive Phase 2 data for the long-acting anti–IL-13 antibody, describing an efficacy signal that could support Phase 3 execution. The company signaled discussions with regulators as it prepares the pivotal program. For competitors, the financing and the Phase 3 roadmap raise the odds that the anti–IL-13 class will see further differentiation on dosing duration and outcomes, particularly in moderate-to-severe disease.